

Elaine S Jaffe

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9398891/publications.pdf](https://exaly.com/author-pdf/9398891/publications.pdf)

Version: 2024-02-01

566
papers

90,703
citations

291

139
h-index

362

282
g-index

599
all docs

599
docs citations

599
times ranked

52405
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	1.4	6,215
2	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	1.4	3,652
3	WHO-EORTC classification for cutaneous lymphomas. <i>Blood</i> , 2005, 105, 3768-3785.	1.4	3,564
4	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	30.1	3,516
5	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	1.4	1,716
6	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	30.1	1,554
7	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	36.2	1,438
8	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	36.2	1,319
9	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	30.1	1,301
10	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	30.1	1,158
11	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.8	1,008
12	The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. <i>Blood</i> , 2019, 133, 1703-1714.	1.4	916
13	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	7.6	879
14	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	16.8	851
15	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	15.4	844
16	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	27.8	841
17	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	30.1	829
18	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	20.9	795

#	ARTICLE	IF	CITATIONS
19	ALK ⁺ anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2008, 111, 5496-5504.	1.4	791
20	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	36.2	772
21	Contemporary classification of histiocytic disorders. <i>Medical and Pediatric Oncology</i> , 1997, 29, 157-166.	1.0	747
22	Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 1996, 20, 103-111.	3.9	741
23	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	15.4	693
24	Spectrum of AIDS-associated malignant disorders. <i>Lancet</i> , The, 1998, 351, 1833-1839.	12.1	691
25	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	646
26	Immunoglobulin-Gene Rearrangements as Unique Clonal Markers in Human Lymphoid Neoplasms. <i>New England Journal of Medicine</i> , 1983, 309, 1593-1599.	30.1	621
27	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	7.2	583
28	Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. <i>Nature Medicine</i> , 1999, 5, 1171-1177.	30.1	577
29	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	1.4	535
30	EBV Positive Mucocutaneous Ulcer—A Study of 26 Cases Associated With Various Sources of Immunosuppression. <i>American Journal of Surgical Pathology</i> , 2010, 34, 405-417.	3.9	515
31	Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 368, 1408-1416.	30.1	493
32	The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1383-1395.	1.2	486
33	The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 523-531.	2.5	484
34	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2009, 113, 6069-6076.	1.4	477
35	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	1.4	449
36	T-Cell Lymphoma Involving Subcutaneous Tissue. <i>American Journal of Surgical Pathology</i> , 1991, 15, 17-27.	3.9	442

#	ARTICLE	IF	CITATIONS
37	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	1.4	434
38	Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. <i>Blood</i> , 2010, 116, e35-e40.	1.4	420
39	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1622-1636.	15.4	417
40	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	415
41	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	1.4	410
42	Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. <i>Blood</i> , 2006, 108, 3786-3791.	1.4	407
43	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017, 31, 833-843.e5.	16.8	406
44	Diffuse Large B-cell Lymphomas With Plasmablastic Differentiation Represent a Heterogeneous Group of Disease Entities. <i>American Journal of Surgical Pathology</i> , 2004, 28, 736-747.	3.9	392
45	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	1.4	387
46	Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. <i>Blood</i> , 1999, 93, 4034-4043.	1.4	372
47	Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. <i>Blood</i> , 2003, 101, 4653-4659.	1.4	369
48	Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. <i>Lancet Oncology</i> , The, 2015, 16, 541-549.	10.8	362
49	Clinical, Immunologic, and Genetic Features of an Autoimmune Lymphoproliferative Syndrome Associated With Abnormal Lymphocyte Apoptosis. <i>Blood</i> , 1997, 89, 1341-1348.	1.4	360
50	Nodular Lymphoma "Evidence for Origin from Follicular B Lymphocytes. <i>New England Journal of Medicine</i> , 1974, 290, 813-819.	30.1	357
51	Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. <i>Journal of Clinical Oncology</i> , 1999, 17, 776-776.	15.4	353
52	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	3.5	351
53	The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. <i>Modern Pathology</i> , 2000, 13, 193-207.	5.6	350
54	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	1.4	349

#	ARTICLE	IF	CITATIONS
55	Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. <i>Blood</i> , 2008, 112, 4384-4399.	1.4	337
56	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005, 106, 4315-4321.	1.4	332
57	High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. <i>Blood</i> , 2005, 105, 496-502.	1.4	325
58	New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 348-348.	15.4	321
59	WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 647-674.	1.5	316
60	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	1.4	314
61	Low-Intensity Therapy in Adults with Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1915-1925.	30.1	314
62	Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. <i>Human Pathology</i> , 1995, 26, 1093-1098.	2.3	310
63	Mediastinal Gray Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1411-1421.	3.9	308
64	FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. <i>Nature Genetics</i> , 1998, 18, 84-87.	20.4	306
65	Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. <i>Blood</i> , 2008, 111, 5433-5439.	1.4	303
66	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	1.4	302
67	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	15.4	300
68	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> , 2002, 99, 2685-2693.	1.4	297
69	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	36.2	295
70	Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. <i>Blood</i> , 2011, 117, 4726-4735.	1.4	289
71	Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. <i>American Journal of Medicine</i> , 1983, 75, 741-749.	1.4	288
72	Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. <i>Blood</i> , 2003, 101, 3407-3412.	1.4	286

#	ARTICLE	IF	CITATIONS
73	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 961-968.	15.4	282
74	Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. <i>Journal of Clinical Oncology</i> , 2008, 26, 2717-2724.	15.4	270
75	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	4.1	267
76	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	16.8	266
77	Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. <i>Blood</i> , 2000, 96, 443-451.	1.4	264
78	Loss of signalling via G13 in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014, 516, 254-258.	36.2	263
79	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018, 132, 2115-2124.	1.4	259
80	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1686-1694.	3.9	255
81	Mycosis fungoides and SÅ©zary syndrome. <i>Lancet, The</i> , 2008, 371, 945-957.	12.1	253
82	Non-Endemic Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 1976, 295, 685-691.	30.1	250
83	Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. <i>Blood</i> , 2006, 108, 1668-1676.	1.4	247
84	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. <i>Blood</i> , 2011, 117, 5835-5849.	1.4	247
85	EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. <i>Blood</i> , 2015, 126, 863-872.	1.4	241
86	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	15.4	234
87	IgVH Mutational Status and Clonality Analysis of Richter's Transformation. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1605-1614.	3.9	233
88	Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. <i>Human Pathology</i> , 1998, 29, 397-403.	2.3	230
89	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	1.4	228
90	In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. <i>Blood</i> , 2002, 99, 3376-3382.	1.4	223

#	ARTICLE	IF	CITATIONS
91	Pathologic and Clinical Spectrum of Post-Thymic T-Cell Malignancies. <i>Cancer Investigation</i> , 1984, 2, 413-426.	1.3	212
92	Pathological Findings in Human Autoimmune Lymphoproliferative Syndrome. <i>American Journal of Pathology</i> , 1998, 153, 1541-1550.	4.1	212
93	Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas. <i>Blood</i> , 1997, 89, 601-609.	1.4	211
94	Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. <i>Blood</i> , 2014, 123, 1989-1999.	1.4	207
95	The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. <i>American Journal of Surgical Pathology</i> , 1984, 8, 263-276.	3.9	206
96	The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 115, 3017-3024.	1.4	206
97	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	1.4	202
98	CCND2 rearrangements are the most frequent genetic events in cyclin D1 ^{hi} mantle cell lymphoma. <i>Blood</i> , 2013, 121, 1394-1402.	1.4	192
99	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. <i>Blood</i> , 2014, 123, 1187-1198.	1.4	192
100	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. <i>Blood</i> , 2019, 133, 1313-1324.	1.4	190
101	Nasal Lymphomas in Peru. <i>American Journal of Surgical Pathology</i> , 1993, 17, 392-399.	3.9	186
102	Cytotoxic Cell Antigen Expression in Anaplastic Large Cell Lymphomas of T- and Null-Cell Type and Hodgkin's Disease: Evidence for Distinct Cellular Origin. <i>Blood</i> , 1997, 89, 980-989.	1.4	184
103	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell ^{hi} diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	8.8	182
104	Anaplastic Large Cell Lymphoma: The Shifting Sands of Diagnostic Hematopathology. <i>Modern Pathology</i> , 2001, 14, 219-228.	5.6	180
105	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	1.4	180
106	Nodular Lymphocyte Predominance Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 526-530.	3.9	178
107	Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. <i>Blood</i> , 2000, 96, 398-404.	1.4	176
108	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	1.4	176

#	ARTICLE	IF	CITATIONS
109	The clinical spectrum of Erdheim-Chester disease: an observational cohort study. <i>Blood Advances</i> , 2017, 1, 357-366.	5.4	176
110	Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. <i>Modern Pathology</i> , 2011, 24, 1421-1432.	5.6	175
111	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	14.2	172
112	Peripheral T-Cell Lymphoma With Reed-Sternberg-like Cells of B-Cell Phenotype and Genotype Associated With Epstein-Barr Virus Infection. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1233.	3.9	168
113	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	15.4	167
114	Lymphocyte Subsets in Normal Human Lymphoid Tissues. <i>American Journal of Clinical Pathology</i> , 1983, 80, 21-30.	0.7	164
115	PTEN Gene Alterations in Lymphoid Neoplasms. <i>Blood</i> , 1998, 92, 3410-3415.	1.4	164
116	NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. <i>Blood</i> , 2011, 117, 1447-1452.	1.4	163
117	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood</i> , 2013, 122, 3599-3606.	1.4	163
118	The Role of Mig, the Monokine Induced by Interferon- γ , and IP-10, the Interferon- γ -Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease. <i>Blood</i> , 1997, 90, 4099-4105.	1.4	162
119	Plasmacytoid Dendritic Cells. <i>Advances in Anatomic Pathology</i> , 2009, 16, 392-404.	4.4	162
120	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , the, 2018, 5, e609-e617.	4.6	162
121	Immunologic aspects and pathology of the malignant lymphomas. <i>Cancer</i> , 1978, 42, 911-921.	4.1	158
122	Marginal Zone B-Cell Lymphoma in Children and Young Adults. <i>American Journal of Surgical Pathology</i> , 2003, 27, 522-531.	3.9	158
123	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	7.2	157
124	Composite Low Grade B-Cell Lymphomas with Two Immunophenotypically Distinct Cell Populations Are True Biclinal Lymphomas. <i>American Journal of Pathology</i> , 1999, 154, 1857-1866.	4.1	153
125	Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. <i>Haematologica</i> , 2010, 95, 1873-1879.	3.5	153
126	Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. <i>Modern Pathology</i> , 2010, 23, 991-999.	5.6	153

#	ARTICLE	IF	CITATIONS
127	Follicular Lymphomas in Children and Young Adults. <i>American Journal of Surgical Pathology</i> , 2013, 37, 333-343.	3.9	152
128	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	7.6	152
129	Histologic Features of Sinus Histiocytosis With Massive Lymphadenopathy in Patients With Autoimmune Lymphoproliferative Syndrome. <i>American Journal of Surgical Pathology</i> , 2005, 29, 903-911.	3.9	150
130	ï¿† T-Cell Lymphoma of the Skin. <i>Archives of Dermatology</i> , 2000, 136, 1024-32.	1.4	148
131	Primary Nodal Marginal Zone Lymphomas of Splenic and MALT Type. <i>American Journal of Surgical Pathology</i> , 1999, 23, 59-68.	3.9	148
132	Alkaline Phosphatase-positive Malignant Lymphoma: A Subtype of B-cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 1977, 68, 535-542.	0.7	147
133	Angiocentric immunoproliferative lesions: A molecular analysis of eight casesâ†. <i>Human Pathology</i> , 1991, 22, 1150-1157.	2.3	147
134	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Reed-Sternbergâ€“Like Cells and Possible Transformation to Hodgkinâ€™s Disease. <i>American Journal of Surgical Pathology</i> , 1992, 16, 859-867.	3.9	146
135	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. <i>Haematologica</i> , 2012, 97, 270-278.	3.5	146
136	Localization of Epstein-Barr Viral Genomes in Angiocentric Immunoproliferative Lesions. <i>American Journal of Surgical Pathology</i> , 1992, 16, 439-447.	3.9	145
137	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. <i>British Journal of Haematology</i> , 2007, 136, 286-293.	2.7	145
138	Peripheral Tâ€“cell and <sc>NK</sc>â€“cell lymphomas and their mimics; taking a step forward â€“ report on the lymphoma workshop of the <sc>XVI</sc>th meeting of the European Association for Haematopathology and the Society for Hematopathology. <i>Histopathology</i> , 2014, 64, 171-199.	3.1	145
139	Mutation and genomic deletion status of <i>ataxia telangiectasia mutated</i> (<i>ATM</i>) and <i>p53</i> confer specific gene expression profiles in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2352-2357.	7.6	142
140	Cutaneous Lymphomatoid Granulomatosis. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1111-1120.	3.9	140
141	Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. <i>Blood</i> , 2004, 103, 1244-1252.	1.4	140
142	Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. <i>Blood</i> , 2011, 118, 2976-2984.	1.4	140
143	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. <i>Modern Pathology</i> , 2011, 24, 1586-1597.	5.6	139
144	Differential Chemokine Expression in Tissues Involved by Hodgkinâ€™s Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. <i>Blood</i> , 1999, 93, 2463-2470.	1.4	138

#	ARTICLE	IF	CITATIONS
145	Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, e215-e218.	3.5	138
146	Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. <i>Haematologica</i> , 2011, 96, 558-566.	3.5	137
147	Sjögren's syndrome-like illness associated with the acquired immunodeficiency syndrome-related complex. <i>Human Pathology</i> , 1987, 18, 1063-1068.	2.3	134
148	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. <i>Cancer Discovery</i> , 2014, 4, 480-493.	14.2	134
149	Hodgkin Lymphoma: An Update on its Biology with New Insights into Classification. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 206-216.	1.8	131
150	Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. <i>Blood</i> , 2010, 115, 5164-5169.	1.4	131
151	Lymphomatoid Granulomatosis—A Single Institute Experience. <i>American Journal of Surgical Pathology</i> , 2015, 39, 141-156.	3.9	128
152	Peripheral T-Cell Lymphoma with Aberrant Expression of CD79a and CD20: A Diagnostic Pitfall. <i>Modern Pathology</i> , 2001, 14, 105-110.	5.6	127
153	Reproducing the molecular subclassification of peripheral T-cell lymphoma—NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	1.4	127
154	Diagnosis of Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2019, 184, 45-59.	2.7	127
155	Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas. <i>Blood</i> , 1998, 92, 1308-1316.	1.4	126
156	Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH. <i>Journal of Clinical Oncology</i> , 2000, 18, 3633-3642.	15.4	126
157	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016, 30, 764-778.	16.8	126
158	Lymphoproliferative Lesions in Patients with Common Variable Immunodeficiency Syndrome. <i>American Journal of Surgical Pathology</i> , 1992, 16, 1170-1182.	3.9	124
159	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010, 116, 953-961.	1.4	123
160	Nonhepatosplenic $\gamma\delta$ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1214-1225.	3.9	121
161	Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2007, 25, 3321-3329.	15.4	120
162	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , 2016, 128, 1101-1111.	1.4	120

#	ARTICLE	IF	CITATIONS
163	Hodgkin's Disease and Lymphoproliferations Resembling Hodgkin's Disease in Patients Receiving Long-Term Low-Dose Methotrexate Therapy. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1279-1287.	3.9	120
164	Lymphocytic lymphoma of intermediate differentiationâ€”Mantle zone lymphoma: A distinct subtype of B-cell lymphoma. <i>Human Pathology</i> , 1987, 18, 877-880.	2.3	119
165	CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2479-2479.	15.4	119
166	Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. <i>Current Opinion in Hematology</i> , 2007, 14, 348-353.	2.6	116
167	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	15.4	115
168	Peripheral T-cell Lymphomas of Follicular T-Helper Cell Derivation With Hodgkin/Reed-Sternberg Cells of B-cell Lineage. <i>American Journal of Surgical Pathology</i> , 2013, 37, 816-826.	3.9	115
169	T-Cell Lymphoblastic Lymphoma With Eosinophilia Associated With Subsequent Myeloid Malignancy. <i>American Journal of Surgical Pathology</i> , 1992, 16, 236-245.	3.9	114
170	Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. <i>Lancet Oncology</i> , The, 2005, 6, 435-437.	10.8	114
171	Lymphoblastic lymphoma presenting in cutaneous sites. <i>Journal of the American Academy of Dermatology</i> , 1991, 25, 1023-1031.	1.2	113
172	Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. <i>Blood</i> , 2001, 97, 3161-3170.	1.4	112
173	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	1.4	112
174	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	1.4	112
175	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. <i>Haematologica</i> , 2012, 97, 586-594.	3.5	111
176	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2016, 40, 36-43.	3.9	111
177	Composite Lymphoma: <i>A Clinicopathologic Analysis of Nine Patients with Hodgkin's Disease and B-Cell Non-Hodgkin's Lymphoma</i>. <i>American Journal of Clinical Pathology</i> , 1991, 96, 81-89.	0.7	109
178	Mantle Cell Lymphomas Lack Expression of p27kip1, a Cyclin-Dependent Kinase Inhibitor. <i>American Journal of Pathology</i> , 1998, 153, 175-182.	4.1	109
179	Peripheral T-Cell Lymphomas Expressing CD30 and CD15. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1513-1522.	3.9	108
180	Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. <i>Modern Pathology</i> , 2013, 26, S71-S87.	5.6	108

#	ARTICLE	IF	CITATIONS
181	Classification of cytotoxic T-cell and natural killer cell lymphomas. <i>Seminars in Hematology</i> , 2003, 40, 175-184.	4.0	107
182	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. <i>Nature Medicine</i> , 2005, 11, 986-991.	30.1	107
183	Primary follicular lymphoma of the testis in childhood. <i>Cancer</i> , 1999, 85, 1626-1635.	4.1	105
184	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	15.4	105
185	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	1.4	104
186	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	3.5	104
187	The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 411-420.	2.0	103
188	A prospective study of mediastinal gray-zone lymphoma. <i>Blood</i> , 2014, 124, 1563-1569.	1.4	103
189	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	15.4	101
190	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1458-1466.	3.9	100
191	The Pathology of NK-Cell Lymphomas and Leukemias. <i>Advances in Anatomic Pathology</i> , 2005, 12, 27-34.	4.4	100
192	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5337-5351.	8.2	100
193	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	1.4	99
194	A subset of Rosaiâ€Dorfman disease cases show increased IgG4â€positive plasma cells: another red herring or a true association with IgG4â€related disease?. <i>Histopathology</i> , 2014, 64, 455-459.	3.1	99
195	Multicentric Castleman disease: Where are we now?. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 294-306.	2.2	99
196	Increased expression of the PRADâ€1/CCND1 gene in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 1025-1030.	2.7	97
197	Pathology of Castleman Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 37-52.	2.0	96
198	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761.	1.4	96

#	ARTICLE	IF	CITATIONS
199	Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. <i>Lancet Oncology</i> , 2004, 5, 248-250.	10.8	95
200	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	16.8	95
201	Structural and functional properties of the "hairy" cells of leukemic reticuloendotheliosis. <i>Cancer</i> , 1978, 41, 210-227.	4.1	94
202	The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. <i>Blood</i> , 2003, 101, 3590-3593.	1.4	94
203	Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. <i>Haematologica</i> , 2011, 96, 262-268.	3.5	93
204	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	1.4	93
205	Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 506-514.	2.5	92
206	Pulmonary Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Arising in a Pediatric HIV-Positive Patient. <i>American Journal of Surgical Pathology</i> , 1995, 19, 357-363.	3.9	91
207	Non-Hodgkin's Lymphoma in Job's Syndrome: A Case Report and Literature Review. <i>Leukemia and Lymphoma</i> , 2004, 45, 2521-2525.	1.4	91
208	Early lesions of follicular lymphoma: a genetic perspective. <i>Haematologica</i> , 2014, 99, 481-488.	3.5	91
209	Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. <i>Blood</i> , 2018, 132, 1871-1878.	1.4	90
210	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. <i>Blood</i> , 2020, 135, 274-286.	1.4	89
211	Malignant lymphoma obscured by concomitant extensive epithelioid granulomas. Report of three cases with similar clinicopathologic features. <i>Cancer</i> , 1977, 39, 1146-1155.	4.1	88
212	Epstein-Barr Virus Is Infrequently Identified in Non-Hodgkin's Lymphomas Associated with Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 48-61.	3.9	86
213	EBV-Positive B-Cell Proliferations of Varied Malignant Potential. <i>American Journal of Clinical Pathology</i> , 2017, 147, 129-152.	0.7	86
214	Increased Incidence of Hodgkin's Disease After Allogeneic Bone Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 1999, 17, 3122-3127.	15.4	85
215	Lymphoid Lesions of the Head and Neck: A Model of Lymphocyte Homing and Lymphomagenesis. <i>Modern Pathology</i> , 2002, 15, 255-263.	5.6	84
216	Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. <i>Laboratory Investigation</i> , 2004, 84, 235-244.	3.9	84

#	ARTICLE	IF	CITATIONS
217	Receptors for Complement and Immunoglobulin on Human and Animal Lymphoid Cells. <i>Immunological Reviews</i> , 1973, 16, 3-28.	6.1	83
218	The Role of Chemokines in Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2000, 38, 363-371.	1.4	83
219	Cytotoxic T-cell and NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, e60-e71.	3.9	83
220	Lymphoma Classification. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 176-185.	2.0	82
221	Chronic Lymphocytic Leukemia with Coexistent Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1991, 15, 33-42.	3.9	81
222	Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. <i>Blood</i> , 2003, 101, 3181-3187.	1.4	81
223	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 ^{hi} mantle cell lymphoma. <i>Blood</i> , 2019, 133, 940-951.	1.4	81
224	Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features. <i>Cancer</i> , 1984, 54, 1310-1317.	4.1	80
225	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008, 93, 1327-1334.	3.5	80
226	Cell volumes and dna distributions of normal and neoplastic human lymphoid cells. <i>Cancer</i> , 1978, 41, 201-209.	4.1	79
227	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. <i>Blood Advances</i> , 2020, 4, 5652-5665.	5.4	79
228	Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> , 2022, 140, 2193-2227.	1.4	79
229	Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. <i>Blood</i> , 2020, 135, 1344-1352.	1.4	78
230	Immunologic and morphologic studies of T cell lymphoma. <i>American Journal of Medicine</i> , 1975, 58, 307-313.	1.4	77
231	Pathobiology of Peripheral T-cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 317-322.	2.5	77
232	MicroRNA profiles of t(14;18) ⁻ negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	1.4	77
233	IgD Positive L&H Cells Identify a Unique Subset of Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2006, 30, 585-592.	3.9	75
234	Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. <i>Haematologica</i> , 2009, 94, 1618-1622.	3.5	75

#	ARTICLE	IF	CITATIONS
235	Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis with comparison to Hodgkin-like lesion. <i>Human Pathology</i> , 2016, 55, 108-116.	2.3	75
236	HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2017, 147, 171-187.	0.7	75
237	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	1.4	74
238	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016, 101, 976-984.	3.5	74
239	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. <i>Haematologica</i> , 2019, 104, 1822-1829.	3.5	74
240	EBV May Be Expressed in the LP Cells of Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults. <i>American Journal of Surgical Pathology</i> , 2014, 38, 316-324.	3.9	73
241	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. <i>Blood</i> , 2019, 133, 962-966.	1.4	73
242	Peripheral t cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. <i>American Journal of Medicine</i> , 1987, 82, 539-545.	1.4	72
243	The Histological Classification of Diffuse Large B-cell Lymphomas. <i>Seminars in Hematology</i> , 2015, 52, 57-66.	4.0	72
244	Special Report: Quality Control in Immunohistochemistry: Report of a Workshop Sponsored by the Biological Stain Commission. <i>American Journal of Clinical Pathology</i> , 1989, 92, 836-843.	0.7	71
245	Molecular Profiling Provides Evidence of Primary Mediastinal Large B-Cell Lymphoma as a Distinct Entity Related to Classic Hodgkin Lymphoma. <i>Advances in Anatomic Pathology</i> , 2004, 11, 227-238.	4.4	71
246	Automatic Classification of Lymphoma Images With Transform-Based Global Features. <i>IEEE Transactions on Information Technology in Biomedicine</i> , 2010, 14, 1003-1013.	3.4	71
247	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. <i>Blood</i> , 2017, 130, 323-327.	1.4	71
248	Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR. <i>Modern Pathology</i> , 2010, 23, 866-873.	5.6	70
249	Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases. <i>Modern Pathology</i> , 2011, 24, 355-366.	5.6	70
250	Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 20-25.	0.4	70
251	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	1.4	69
252	Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. <i>Blood</i> , 2012, 120, 3756-3763.	1.4	69

#	ARTICLE	IF	CITATIONS
253	Acute Infectious Mononucleosis: CD30 (Ki-1) Antigen Expression and Histologic Correlations. American Journal of Clinical Pathology, 1990, 93, 698-702.	0.7	68
254	The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Seminars in Oncology, 2002, 29, 41-47.	2.3	68
255	Histopathology of Hodgkin's Lymphoma. Cancer Journal (Sudbury, Mass), 2009, 15, 129-137.	2.0	68
256	Gall Bladder and Extrahepatic Bile Duct Lymphomas: Clinicopathological Observations and Biological Implications. American Journal of Surgical Pathology, 2010, 34, 1277-1286.	3.9	68
257	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. Clinical Cancer Research, 2011, 17, 3727-3732.	7.2	68
258	Cytokine receptor signaling is required for the survival of ALK ⁺ anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3975-3980.	7.6	68
259	Hairy Cell Leukemia: A B Cell Neoplasm with a Unique Antigenic Phenotype. American Journal of Clinical Pathology, 1983, 80, 421-428.	0.7	67
260	Clonal T-cell Populations and Increased Risk for Cytotoxic T-cell Lymphomas in B-CLL Patients. American Journal of Surgical Pathology, 2004, 28, 849-858.	3.9	67
261	The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology American Society of Hematology Education Program, 2009, 2009, 523-531.	2.5	67
262	The Revised European-American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. Journal of Cutaneous Pathology, 1997, 24, 329-341.	1.5	66
263	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 2017, 130, 1819-1831.	1.4	66
264	Interleukin-18, Interferon- γ , IP-10, and Mig Expression in Epstein-Barr Virus-Induced Infectious Mononucleosis and Posttransplant Lymphoproliferative Disease. American Journal of Pathology, 1999, 155, 257-265.	4.1	65
265	Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2020, 38, 1102-1111.	15.4	65
266	Immunodeficiency-Associated Malignant Lymphoma. American Journal of Surgical Pathology, 1994, 18, 1092-1101.	3.9	64
267	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances, 2017, 1, 2600-2609.	5.4	64
268	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood, 2018, 132, 2401-2405.	1.4	64
269	End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica, 2018, 103, 1337-1344.	3.5	64
270	Aggressive Langerhans cell histiocytosis following T-ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. American Journal of Hematology, 2008, 83, 116-121.	4.3	63

#	ARTICLE	IF	CITATIONS
271	Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. <i>Blood</i> , 2013, 121, 1795-1804.	1.4	63
272	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	3.9	63
273	<i>bcl-1</i> Rearrangement and Cyclin D1 Protein Expression in Multiple Lymphomatous Polyposis. <i>American Journal of Clinical Pathology</i> , 1996, 105, 737-743.	0.7	62
274	T-cell-rich B-cell lymphoma presenting in skin. <i>Journal of Cutaneous Pathology</i> , 1996, 23, 101-108.	1.5	62
275	Hairy cell leukemia: Enzyme histochemical characterization, with special reference to splenic stromal changes. <i>Cancer</i> , 1977, 39, 2323-2336.	4.1	61
276	Non-Hodgkin's Lymphomas Arising in Patients Successfully Treated for Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1992, 16, 885-895.	3.9	61
277	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	7.6	61
278	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. <i>Haematologica</i> , 2020, 105, 951-960.	3.5	61
279	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014, 155, 176-187.	3.3	60
280	The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt. Epidemiologic correlations. <i>Cancer</i> , 1995, 76, 1245-1252.	4.1	59
281	A Biphenotypic Human Herpesvirus 8-Associated Primary Bowel Lymphoma. <i>American Journal of Surgical Pathology</i> , 1999, 23, 992.	3.9	59
282	Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. <i>Haematologica</i> , 2010, 95, 449-455.	3.5	59
283	Lymphocytic Lymphoma of Intermediate Differentiation: Morphologic, Immunophenotypic, and Prognostic Factors. <i>Journal of the National Cancer Institute</i> , 1990, 82, 742-748.	6.4	58
284	Clinical and Histoimmunophenotypic Findings and Association with Epstein-Barr Virus in 16 Cases. <i>American Journal of Surgical Pathology</i> , 1995, 19, 1431-1439.	3.9	57
285	Nodal Involvement by Cutaneous CD30-positive T-cell Lymphoma Mimicking Classical Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 716-725.	3.9	57
286	Cutaneous Manifestations of Lymphoma: A Clinical Guide Based on the WHO Classification. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 86-100.	2.2	56
287	Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: A lymphoma of low malignant potential. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1165-1170.	1.6	56
288	Hepatobiliary Lymphoepithelioma-Like Carcinoma Associated With Epstein-Barr Virus. <i>American Journal of Clinical Pathology</i> , 1998, 109, 90-95.	0.7	55

#	ARTICLE	IF	CITATIONS
289	Primary Cutaneous CD30-Positive Anaplastic Large Cell Lymphoma in Childhood: Report of 4 Cases and Review of the Literature. <i>Pediatric and Developmental Pathology</i> , 2005, 8, 52-60.	1.0	55
290	The Elusive Reedâ€“Sternberg Cell. <i>New England Journal of Medicine</i> , 1989, 320, 529-531.	30.1	54
291	IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. <i>Blood</i> , 2008, 112, 3818-3826.	1.4	54
292	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	1.4	54
293	Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 241-247.	2.3	54
294	Primary CNS T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1719-1729.	3.9	54
295	Romidepsin in peripheral and cutaneous Tâ€“cell lymphoma: mechanistic implications from clinical and correlative data. <i>British Journal of Haematology</i> , 2015, 170, 96-109.	2.7	54
296	PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 89-91.	30.1	54
297	CD5 Expression in B-Cell Small Lymphocytic Malignancies. <i>American Journal of Surgical Pathology</i> , 1992, 16, 130-137.	3.9	53
298	Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. <i>Blood</i> , 2004, 104, 3355-3357.	1.4	53
299	IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. <i>Blood</i> , 2018, 132, 2280-2285.	1.4	53
300	Primary Mediastinal Large B-Cell Lymphoma, Classic Hodgkin Lymphoma Presenting in the Mediastinum, and Mediastinal Gray Zone Lymphoma: What is the Oncologist To Do?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 157-163.	2.3	52
301	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. <i>Modern Pathology</i> , 2013, 26, 1329-1337.	5.6	52
302	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <i>Haematologica</i> , 2014, 99, 1421-1432.	3.5	52
303	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 693-701.	1.4	51
304	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016, 22, 310-318.	7.2	50
305	Hydroa vacciniformeâ€“like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites. <i>Blood</i> , 2019, 133, 2753-2764.	1.4	50
306	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	3.5	50

#	ARTICLE	IF	CITATIONS
307	Diffuse large cell lymphomas (reticulum cell sarcomas, histiocytic lymphomas). Correlation of morphologic features with functional markers. <i>Cancer</i> , 1980, 46, 1428-1441.	4.1	48
308	Hodgkin's disease in Mexico. Prevalence of Epstein-Barr virus sequences and correlations with histologic subtype. <i>Cancer</i> , 1995, 75, 1360-1366.	4.1	48
309	Histologically Discordant Lymphomas With B-Cell and T-Cell Components. <i>American Journal of Clinical Pathology</i> , 1997, 108, 316-323.	0.7	48
310	Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays. <i>Modern Pathology</i> , 2001, 14, 1270-1276.	5.6	48
311	CD5+ Follicular Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 118, 589-598.	0.7	48
312	Nature and importance of follicular lymphoma precursors. <i>Haematologica</i> , 2014, 99, 802-810.	3.5	48
313	How I Diagnose Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2021, 156, 1-14.	0.7	48
314	Acute megakaryoblastic leukemia in childhood. <i>Cancer</i> , 1984, 54, 1423-1428.	4.1	47
315	NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein β^2 in ALK-positive anaplastic large cell lymphoma. <i>Blood</i> , 2006, 108, 2029-2036.	1.4	47
316	Development of Disseminated Histiocytic Sarcoma in a Patient With Autoimmune Lymphoproliferative Syndrome and Associated Rosai-Dorfman Disease. <i>American Journal of Surgical Pathology</i> , 2010, 34, 589-594.	3.9	47
317	Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the <i>CCND1</i> gene locus. <i>Leukemia and Lymphoma</i> , 2011, 52, 458-466.	1.4	47
318	Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. <i>Cytometry Part B - Clinical Cytometry</i> , 2005, 67B, 6-12.	1.7	46
319	T-cell/histiocyte-rich large B-cell lymphoma. <i>Haematologica</i> , 2010, 95, 352-356.	3.5	46
320	Adult T-Cell leukemia/lymphoma: A working point-score classification for epidemiological studies. <i>International Journal of Cancer</i> , 1994, 59, 491-493.	5.4	45
321	Multilocular thymic cysts in children with human immunodeficiency virus infection: Clinical and pathologic aspects. <i>Journal of Pediatrics</i> , 1997, 131, 264-270.	2.2	45
322	Common Threads of Mucosa-Associated Lymphoid Tissue Lymphoma Pathogenesis: From Infection to Translocation. <i>Journal of the National Cancer Institute</i> , 2004, 96, 571-573.	6.4	45
323	Follicular lymphomas with plasmacytic differentiation include two subtypes. <i>Modern Pathology</i> , 2010, 23, 71-79.	5.6	45
324	⁹⁰ Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13045-13050.	7.6	45

#	ARTICLE	IF	CITATIONS
325	Recurrent somatic JAK3 mutations in NK-cell enteropathy. <i>Blood</i> , 2019, 134, 986-991.	1.4	45
326	Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. <i>Journal of Pathology</i> , 1999, 189, 288-293.	4.5	44
327	Cutaneous EBV-related lymphoproliferative disorders. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 60-75.	2.2	44
328	Acute lymphoblastic leukemia—hand mirror cell variant: A detailed cytological and ultrastructural study with an analysis of the immunologic surface markers. <i>American Journal of Hematology</i> , 1978, 4, 67-77.	4.3	43
329	Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. <i>Leukemia and Lymphoma</i> , 2020, 61, 808-819.	1.4	43
330	A Comparison of ABC, Unlabeled Antibody and Conjugated Immunohistochemical Methods with Monoclonal and Polyclonal Antibodies—An Examination of Germinal Center of Tonsils. <i>American Journal of Clinical Pathology</i> , 1983, 80, 429-435.	0.7	42
331	Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2014, 142, 347-354.	0.7	42
332	The Revised European-American Classification of Lymphoid Neoplasms (REAL): A Preferred Approach for the Classification of Cutaneous Lymphomas. <i>American Journal of Dermatopathology</i> , 1999, 21, 274-278.	0.6	42
333	Atypical NK-cell Proliferation of the Gastrointestinal Tract in a Patient With Antigliadin Antibodies but not Celiac Disease. <i>American Journal of Surgical Pathology</i> , 2006, 30, 539-544.	3.9	41
334	IgG4-related disease presenting as recurrent mastoiditis. <i>Laryngoscope</i> , 2012, 122, 681-684.	2.1	41
335	Lymphoid Proliferations of Indeterminate Malignant Potential arising in Adults with Common Variable Immunodeficiency Disorders: Unusual Case Studies and Immunohistological Review in the Light of Possible Causative Events. <i>Journal of Clinical Immunology</i> , 2011, 31, 784-791.	3.8	40
336	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670.	5.4	40
337	Human herpesvirus-6-associated acute lymphadenitis in immunocompetent adults. <i>Modern Pathology</i> , 2004, 17, 1427-1433.	5.6	39
338	Nodular Lymphocyte-Predominant Hodgkin Lymphoma With Atypical T Cells. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1666-1678.	3.9	39
339	The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project. <i>American Journal of Hematology</i> , 2012, 87, 790-794.	4.3	39
340	B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency. <i>American Journal of Clinical Pathology</i> , 2017, 147, 153-170.	0.7	39
341	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 69.	6.3	39
342	Low-Grade Follicular Lymphoma of the Small Intestine. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 155-159.	2.3	38

#	ARTICLE	IF	CITATIONS
343	Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 358-366.	4.4	38
344	Expression of the Interferon Regulatory Factor 8/ICSBP-1 in Human Reactive Lymphoid Tissues and B-cell Lymphomas: A Novel Germinal Center Marker. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1190-1200.	3.9	38
345	Multiple recurrences of acute tumor lysis syndrome in an indolent non-hodgkin's lymphoma. <i>Cancer</i> , 1985, 56, 2295-2297.	4.1	37
346	Hodgkin's disease following non-Hodgkin's lymphoma. <i>Cancer</i> , 1992, 69, 2337-2342.	4.1	37
347	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3 ^{dim} /CD4 ⁺ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <i>Modern Pathology</i> , 2016, 29, 1173-1182.	5.6	37
348	CREBBP gene mutations are frequently detected in in situ follicular neoplasia. <i>Blood</i> , 2018, 132, 2687-2690.	1.4	37
349	Primary Cutaneous Hodgkin's Disease with Evolution to Systemic Disease. <i>American Journal of Surgical Pathology</i> , 1996, 20, 754-759.	3.9	37
350	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	3.3	36
351	Angioimmunoblastic T-Cell Lymphoma Partially Obscured by an Epstein-Barr Virus ⁻ Negative Clonal Plasma Cell Proliferation. <i>Journal of Clinical Oncology</i> , 2013, 31, e28-e30.	15.4	36
352	Disease Progression in a Patient With Indolent T-Cell Lymphoproliferative Disease of the Gastrointestinal Tract. <i>International Journal of Surgical Pathology</i> , 2019, 27, 102-107.	0.8	36
353	Lymphomatoid papulosis associated with Ki-1-positive anaplastic large cell lymphoma. A report of two cases and a review of the literature. <i>Cancer</i> , 1994, 74, 3051-3058.	4.1	35
354	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	2.3	35
355	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	4.1	35
356	Diagnosis and classification of lymphoma: Impact of technical advances. <i>Seminars in Hematology</i> , 2019, 56, 30-36.	4.0	35
357	Mediastinal Lymphoblastic Lymphoma With an Immature B-Cell Immunophenotype. <i>American Journal of Surgical Pathology</i> , 1992, 16, 300-305.	3.9	34
358	Hodgkin's Disease Following Non-Hodgkin's Lymphoma. <i>American Journal of Surgical Pathology</i> , 1993, 17, 123-132.	3.9	34
359	Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: Implications for lymphomagenesis. <i>Leukemia and Lymphoma</i> , 2006, 47, 1523-1534.	1.4	34
360	Immunoguided Laser Assisted Microdissection Techniques for DNA Methylation Analysis of Archival Tissue Specimens. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 394-401.	2.9	34

#	ARTICLE	IF	CITATIONS
361	Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome. <i>Histopathology</i> , 2015, 67, 925-927.	3.1	34
362	Early lesions in lymphoid neoplasia. <i>Journal of Hematopathology</i> , 2012, 5, 169-199.	0.5	33
363	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 35-42.	7.2	33
364	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. <i>Modern Pathology</i> , 2021, 34, 336-347.	5.6	33
365	Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. <i>Blood</i> , 2023, 141, 904-916.	1.4	33
366	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.7	32
367	Late-Onset Severe Chronic Active EBV in a Patient for Five Years with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1). <i>Journal of Clinical Immunology</i> , 2015, 35, 445-448.	3.8	32
368	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2020, 1, 155-161.	5.8	32
369	Malignant lymphoma involving a warthin's tumor: A case with immunophenotypic and gene rearrangement analysis. <i>Human Pathology</i> , 1990, 21, 974-977.	2.3	31
370	Marginal Zone B-Cell Lymphoma With Monocytoid B-Cell Lymphocytes in Pediatric Patients Without Immunodeficiency: A Report of Two Cases. <i>American Journal of Clinical Pathology</i> , 1997, 107, 92-98.	0.7	31
371	Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1306-1316.	3.9	31
372	Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic mass. <i>Human Pathology</i> , 2015, 46, 1956-1961.	2.3	30
373	The effect of ethnic differences on the pattern of HTLV-I-associated T-cell leukemia/lymphoma (HATL) in the United States. <i>International Journal of Cancer</i> , 1994, 56, 177-181.	5.4	29
374	Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. <i>Modern Pathology</i> , 2004, 17, 131-135.	5.6	28
375	Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). <i>American Journal of Hematology</i> , 2006, 81, 81-85.	4.3	28
376	B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2018, 42, 269-276.	3.9	28
377	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. <i>Blood</i> , 2020, 136, 2229-2232.	1.4	28
378	The genetic landscape of dural marginal zone lymphomas. <i>Oncotarget</i> , 2016, 7, 43052-43061.	2.1	28

#	ARTICLE	IF	CITATIONS
379	Florid CD4+, CD56+ T-Cell Infiltrate Associated with Herpes Simplex Infection Simulating Nasal NK/T-Cell Lymphoma. <i>Modern Pathology</i> , 2003, 16, 166-172.	5.6	27
380	Hairy cell leukemia diagnostic criteria and differential diagnosis. <i>Leukemia and Lymphoma</i> , 2011, 52, 6-10.	1.4	26
381	CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma. <i>Histopathology</i> , 2011, 58, 803-805.	3.1	26
382	Novel markers in pediatric-type follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 771-779.	2.9	26
383	Mantle Cell Lymphoma: An Update. <i>Leukemia and Lymphoma</i> , 1992, 8, 161-166.	1.4	25
384	Primr kutanes Gamma/Deltaâ€Zellâ€Lymphom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1065-1067.	0.7	25
385	Nodal and Extranodal Plasmacytomas Expressing Immunoglobulin A. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1425-1435.	3.9	25
386	My 4 Antibody Staining of Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Pathology</i> , 1991, 95, 363-368.	0.7	24
387	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e27-e29.	3.5	24
388	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 657-664.	3.9	24
389	An Immunohistochemical Study of the Bone Marrow Lesions of Systemic Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2002, 118, 242-247.	0.7	23
390	Aggressive Epstein-Barr Virus-Associated, CD8+, CD30+, CD56+, Surface CD3â€, Natural Killer (NK)-Like Cytotoxic T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2002, 26, 111-118.	3.9	23
391	Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: <i>in vivo</i> evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2284-2292.	1.4	23
392	Mantle cell lymphoma: A cytopathological and immunocytochemical study. <i>Diagnostic Cytopathology</i> , 1996, 14, 32-37.	1.1	22
393	IL-21â€Driven Neoplasms in SJL Mice Mimic Some Key Features of Human Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Pathology</i> , 2015, 185, 3102-3114.	4.1	22
394	ALK-positive histiocytosis with <i>KIF5B-ALK</i> fusion in an adult female. <i>Haematologica</i> , 2019, 104, e534-e536.	3.5	22
395	Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals. <i>Modern Pathology</i> , 2020, 33, 96-106.	5.6	22
396	Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma. <i>Blood</i> , 2015, 126, 472-472.	1.4	22

#	ARTICLE	IF	CITATIONS
397	Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. <i>Blood</i> , 2000, 96, 443-451.	1.4	22
398	Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2667-2680.	5.4	22
399	A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. <i>Blood Advances</i> , 2022, 6, 4661-4674.	5.4	22
400	DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. <i>Blood</i> , 2022, 140, 1278-1290.	1.4	22
401	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	15.4	22
402	Diagnosing Central Nervous System Lymphoma in the Setting of AIDS: a Step Forward. <i>Journal of the National Cancer Institute</i> , 1998, 90, 346-347.	6.4	21
403	T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting. <i>American Journal of Clinical Pathology</i> , 2017, 147, 188-203.	0.7	21
404	Bone marrow findings in autoimmune lymphoproliferative syndrome with germline <i>FAS</i> mutation. <i>Haematologica</i> , 2017, 102, 364-372.	3.5	21
405	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	4.1	21
406	Immunophenotypic shift of <i>CD4</i> and <i>CD8</i> antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 51-57.	1.5	20
407	Mucocutaneous ulcer: a mimic of EBV+ diffuse large B cell lymphoma in the immunodeficiency setting. <i>Leukemia and Lymphoma</i> , 2016, 57, 1982-1983.	1.4	20
408	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. <i>Seminars in Immunopathology</i> , 1998, 20, 405-423.	4.0	19
409	Coexisting and Clonally Identical Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 767-772.	3.9	19
410	The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 49-52.	1.9	19
411	HHV-8+ positive but EBV-negative primary effusion lymphoma. <i>Blood</i> , 2013, 122, 3712-3712.	1.4	19
412	Clonal Epstein-Barr virus-positive mucocutaneous ulcer mimicking a mature B-cell lymphoma in a patient with mycophenolate-induced immune suppression. <i>Leukemia and Lymphoma</i> , 2015, 56, 1908-1910.	1.4	19
413	Synovitis in angioimmunoblastic lymphadenopathy with dysproteinemia simulating rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 578-582.	6.8	18
414	Genotypic Analysis of Diffuse, Mixed Cell Lymphomas: Comparisons with Morphologic and Immunophenotypic Findings. <i>American Journal of Clinical Pathology</i> , 1991, 95, 547-555.	0.7	18

#	ARTICLE	IF	CITATIONS
415	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. <i>Haematologica</i> , 2009, 94, 596-598.	3.5	18
416	NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2012, 7, 744-750.	1.2	18
417	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020, 1, 100158.	5.9	18
418	Horizontal Transmission of Malignancy: In-Vivo Fusion of Human Lymphomas with Hamster Stroma Produces Tumors Retaining Human Genes and Lymphoid Pathology. <i>PLoS ONE</i> , 2013, 8, e55324.	2.5	18
419	S-100-Positive T-Cell Lymphoproliferative Disorder: A Case Report and Review of the Literature. <i>American Journal of Clinical Pathology</i> , 1994, 102, 478-482.	0.7	17
420	A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn. <i>International Journal of Cancer</i> , 1999, 80, 662-666.	5.4	17
421	Burkitt's/Burkitt's-Like Lymphoma Presenting as Bacterial Sinusitis in Two HIV-Infected Children. <i>AIDS Patient Care and STDs</i> , 2001, 15, 453-458.	2.7	17
422	Lymphomatoid Granulomatosis With Involvement of the Hard Palate: A Case Report. <i>Journal of Oral and Maxillofacial Surgery</i> , 2008, 66, 2161-2163.	1.3	17
423	Transformation of Follicular Lymphoma to Epstein-Barr Virus-Related Hodgkin-Like Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e53-e56.	15.4	17
424	Immunodeficiency and Dysregulation. <i>American Journal of Clinical Pathology</i> , 2017, 147, 124-128.	0.7	17
425	Intravascular large cell lymphoma of NK/T-cell type, EBV positive. <i>Blood</i> , 2017, 130, 837-837.	1.4	17
426	A study of PD-1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. <i>Histopathology</i> , 2019, 75, 282-286.	3.1	17
427	Diagnostic utility of STAT6/EB3 expression in classical Hodgkin lymphoma and related entities. <i>Modern Pathology</i> , 2020, 33, 834-845.	5.6	17
428	Angioimmunoblastic T-cell lymphoma: New insights, but the clinical challenge remains. <i>Annals of Oncology</i> , 1995, 6, 631-632.	1.3	16
429	Chemokine Gene Expression and Clonal Analysis of B Cells in Tissues Involved by Lymphoid Interstitial Pneumonitis from HIV-Infected Pediatric Patients. <i>Modern Pathology</i> , 2001, 14, 929-936.	5.6	16
430	Solitary Extramedullary Plasmacytoma of the Vocal Cord in an Adolescent. <i>Journal of Clinical Oncology</i> , 2009, 27, e244-e247.	15.4	16
431	Cutaneous gamma/delta T-cell lymphoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1065-1067.	0.7	16
432	Pathobiology of T-cell and NK-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 75-87.	1.9	16

#	ARTICLE	IF	CITATIONS
433	Primary/Congenital Immunodeficiency. American Journal of Clinical Pathology, 2017, 147, 204-216.	0.7	16
434	Lack of identifiable vascular invasion in patients with extranodal dissemination of hodgkin's disease. Cancer, 1973, 31, 824-825.	4.1	15
435	Regression and Clonally Distinct Recurrence of Human Immunodeficiency Virus Related Burkitt-Like Lymphoma During Antiretroviral Therapy. Leukemia and Lymphoma, 2001, 42, 1125-1131.	1.4	15
436	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. International Journal of Cancer, 2013, 133, 2852-2863.	5.4	15
437	CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma. HemaSphere, 2021, 5, e505.	2.4	15
438	Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.. Blood, 2006, 108, 2736-2736.	1.4	15
439	Cardiac involvement with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. Leukemia and Lymphoma, 2008, 49, 439-446.	1.4	14
440	Why is it crucial to reintegrate pathology into cancer research?. BioEssays, 2011, 33, 490-498.	2.6	14
441	Phase 1b/2 Study of Viper (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. Blood, 2020, 136, 44-45.	1.4	14
442	Multicentric Castleman disease and the evolution of the concept. Pathologica, 2021, 113, 339-353.	3.1	14
443	Association of EBV Strains, Defined by Multiple Loci Analyses, in Non-Hodgkin Lymphomas and Reactive Tissues from HIV Positive and HIV Negative Patients. Leukemia and Lymphoma, 2000, 37, 425-429.	1.4	13
444	Peripheral T-Cell Lymphoma With Aberrant Expression of CD30, CD15, and CD20. Journal of Clinical Oncology, 2011, 29, e789-e791.	15.4	13
445	Antineutrophil Cytoplasmic Autoantibody-associated Systemic Vasculitis is Associated With Epstein-Barr Virus in the Setting of HIV Infection. Infectious Diseases in Clinical Practice, 2013, 21, 50-53.	0.3	13
446	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia and Lymphoma, 2016, 57, 717-720.	1.4	13
447	Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes. Seminars in Diagnostic Pathology, 2018, 35, 20-33.	2.2	13
448	<i>MYC</i> gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leukemia and Lymphoma, 2018, 59, 505-508.	1.4	13
449	Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim-Chester Disease. Journal of Clinical Medicine, 2018, 7, 243.	2.5	13
450	An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract. American Journal of Surgical Pathology, 2020, 44, 561-565.	3.9	13

#	ARTICLE	IF	CITATIONS
451	Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).. Blood, 2004, 104, 3111-3111.	1.4	13
452	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. Blood, 2018, 132, 147-147.	1.4	12
453	A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies.. Blood, 2005, 106, 3348-3348.	1.4	12
454	Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma. Blood, 2017, 130, 1683-1683.	1.4	11
455	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. PLoS Pathogens, 2018, 14, e1007130.	4.1	11
456	Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).. Blood, 2009, 114, 106-106.	1.4	11
457	Phase I dose escalation study of the anti-CD2 monoclonal antibody, sipilizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leukemia and Lymphoma, 2018, 59, 1466-1469.	1.4	10
458	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 213-225.	7.2	10
459	Taking gray zone lymphomas out of the shadows. Blood, 2021, 137, 1703-1704.	1.4	10
460	Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. Modern Pathology, 2004, 17, 131-135.	5.6	10
461	Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survival. Leukemia and Lymphoma, 2008, 49, 1403-1406.	1.4	9
462	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Leukemia and Lymphoma, 2009, 50, 1875-1878.	1.4	9
463	Increased CD56-positive polyclonal B cells in Castleman disease: a diagnostic pitfall. Histopathology, 2013, 63, 877-880.	3.1	9
464	Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL. Blood Advances, 2021, 5, 4198-4210.	5.4	9
465	Neutrophil and Eosinophil Extracellular Traps in Hodgkin Lymphoma. HemaSphere, 2021, 5, e633.	2.4	9
466	Response to "The WHO classification of haematolymphoid tumours" (Editorial). Leukemia, 2022, 36, 2748-2749.	7.5	9
467	Recommendations for the reporting of lymphoid neoplasms: A report from the association of directors of anatomic and surgical pathology. The Ad Hoc Committee on reporting of lymphoid neoplasms. Human Pathology, 2002, 33, 1064-1068.	2.3	8
468	Human Herpes Virus 6 (HHV-6)-associated Lymphadenitis. American Journal of Surgical Pathology, 2018, 42, 1402-1408.	3.9	8

#	ARTICLE	IF	CITATIONS
469	Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1340-1352.	3.9	8
470	T-cell and NK-cell neoplasms of the gastrointestinal tract – recurrent themes, but clinical and biological distinctions exist. <i>Haematologica</i> , 2020, 105, 1760-1762.	3.5	8
471	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. <i>Blood</i> , 2013, 122, 3029-3029.	1.4	8
472	Clinical, Immunologic, and Virologic Findings in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Lymphomas Suggest KSHV-Associated Inflammatory Syndromes Contribute to Symptoms and Disease Pathogenesis.. <i>Blood</i> , 2012, 120, 2708-2708.	1.4	8
473	Human t-cell leukemia virus-i and hematologic malignancies in panama. <i>Cancer</i> , 1989, 63, 2186-2191.	4.1	7
474	Classification and Histopathology of the Lymphomas. , 2006, , 2-38.		7
475	Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 468-472.	2.9	7
476	Genetic Diversity in Melanoma Metastases from a Patient with Xeroderma Pigmentosum. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1188-1191.	0.7	7
477	Follicular lymphomas: a tapestry of common and contrasting threads. <i>Haematologica</i> , 2013, 98, 1163-1165.	3.5	7
478	Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 2238-2242.	7.5	7
479	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	7
480	A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin™s Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.. <i>Blood</i> , 2006, 108, 98-98.	1.4	7
481	Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 3672-3672.	1.4	7
482	Clinicopathologic and Molecular Characterization of Epstein-Barr Virus–positive Plasmacytoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1364-1379.	3.9	7
483	Commentary on –Pathologic Diagnosis of Mantle Cell Lymphoma– Clinical Lymphoma and Myeloma, 2000, 1, 207-208.	2.2	6
484	Mature T-Cell and NK-Cell Lymphomas in the Pediatric Age Group. <i>Pathology Patterns Reviews</i> , 2004, 122, S110-S121.	0.3	6
485	XII. Gray zone lymphomas: a biological experiment, and a challenge for diagnosis and management. <i>Annals of Oncology</i> , 2011, 22, iv64-iv66.	1.3	6
486	18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome. <i>Clinical Nuclear Medicine</i> , 2019, 44, 949-955.	1.5	6

#	ARTICLE	IF	CITATIONS
487	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2062-2066.	1.4	6
488	Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R. <i>Blood</i> , 2008, 112, 3590-3590.	1.4	6
489	A novel approach for characterization of <scp>KSHV</scp>â€associated multicentric Castleman disease from effusions. <i>British Journal of Haematology</i> , 2023, 200, 462-475.	2.7	6
490	Follicle Center Lymphoma (FCL) of the Lower Female Genital Tract (LFGT). <i>American Journal of Surgical Pathology</i> , 2023, 47, 409-419.	3.9	6
491	Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma. <i>British Journal of Haematology</i> , 2002, 116, 329-333.	2.7	5
492	TAFRO syndrome: A case report and review of the literature. <i>Human Pathology: Case Reports</i> , 2017, 10, 1-4.	0.2	5
493	The Microscope as a Tool for Disease Discoveryâ€”A Personal Voyage. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 1-24.	23.4	5
494	Use of the Polymerase Chain Reaction Technique to Determine c-myc Expression in Follicular Center Cell Lymphoma. <i>Diagnostic Molecular Pathology</i> , 1996, 5, 20-25.	2.0	4
495	Successful Treatment of a Patient With Epstein-Barr Virusâ€”Positive B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e658-e660.	15.4	4
496	Centralized Review Offers Promise for the Clinician, the Pathologist, and the Patient With Newly Diagnosed Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1398-1399.	15.4	4
497	t(14;18)-positive B cells: is it seed or soil?. <i>Blood</i> , 2018, 132, 1631-1632.	1.4	4
498	Phase 1b Study of Viper (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , 2019, 134, 2867-2867.	1.4	4
499	Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142). <i>Blood</i> , 2020, 136, 8-9.	1.4	4
500	Evolution in the Definition of Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: A Model for the Future of Personalized Medicine. <i>Hemato</i> , 2022, 3, 466-474.	0.6	4
501	Surface light chain phenotype in indolent lymphomas: Lack of prognostic significance. <i>American Journal of Hematology</i> , 1990, 34, 15-20.	4.3	3
502	Response during radiotherapy may be associated with outcome in mediastinal Hodgkin's disease. <i>Radiation Oncology Investigations</i> , 1998, 6, 216-225.	1.0	3
503	Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review. <i>Human Pathology: Case Reports</i> , 2019, 17, 200302.	0.2	3
504	CD30⁺ large B cell lymphoma with anaplastic features and complete loss of B cell marker expression arising from follicular lymphoma. <i>Histopathology</i> , 2019, 75, 602-605.	3.1	3

#	ARTICLE	IF	CITATIONS
505	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. <i>Seminars in Immunopathology</i> , 1998, 20, 405-423.	4.0	3
506	Authors' Reply: Pulmonary Lymphoma in an Immunocompromised Host. <i>American Journal of Surgical Pathology</i> , 1996, 20, 644.	3.9	3
507	DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 1767-1767.	1.4	3
508	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. <i>Blood</i> , 2000, 96, 1900-1905.	1.4	3
509	Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression. <i>Blood</i> , 2012, 120, 150-150.	1.4	3
510	Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. <i>Blood</i> , 2021, 138, 4504-4504.	1.4	3
511	Histiocytoses converge through common pathways. <i>Blood</i> , 2022, 139, 157-159.	1.4	3
512	Lymphoma Nomenclature –What's in a name?. <i>British Journal of Haematology</i> , 2022, 197, 539-543.	2.7	3
513	Core biopsy for lymphoma diagnosis? A needling prospect. <i>Blood</i> , 2022, 140, 2525-2527.	1.4	3
514	Cutaneous lymphomas: it's location, location, location. <i>Blood</i> , 2005, 105, 3394-3395.	1.4	2
515	Adrenal Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 341-341.	2.7	2
516	A window into cutaneous adult T-cell leukemia/lymphoma. <i>Blood</i> , 2015, 126, 920-920.	1.4	2
517	Lymphoid hyperplasia with atypical dendritic/Langerhans cell proliferation mimicking Hodgkin lymphoma. <i>Histopathology</i> , 2019, 74, 797-799.	3.1	2
518	Reply to M. Romero et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2819-2820.	15.4	2
519	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 356-356.	1.4	2
520	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 679-679.	1.4	2
521	Hodgkin Lymphoma Variant of Richter Transformation: Morphology, EBV Status, Clonality and Survival Analysis a Retrospective Study of 77 Patients. <i>Blood</i> , 2015, 126, 2637-2637.	1.4	2
522	Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMP study. <i>Blood</i> , 0, , .	1.4	2

#	ARTICLE	IF	CITATIONS
523	Calcification in benign non-functioning adrenal adenoma. Report of a case with selective adrenal arteriogram. British Journal of Radiology, 1972, 45, 621-623.	2.3	1
524	Introduction to Diagnostic Problems in Angioimmunoblastic Lymphadenopathy. American Journal of Surgical Pathology, 1991, 15, 193.	3.9	1
525	Avidin-Biotin Labeling of Cellular Antigens in Cryostat-Sectioned Tissue. Methods in Molecular Biology, 1999, 115, 215-222.	0.0	1
526	Durable Remission of Mantle Cell Lymphoma Relapsing a Third Time After Allogeneic Hematopoietic Stem Cell Transplantation Treated With Rituximab, Bortezomib, Donor Lymphocytes, and Pegylated Interferon. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, e1-e5.	0.4	1
527	The Pathologic Basis for the Classification of Non-Hodgkin and Hodgkin Lymphomas. , 2018, , 1187-1203.		1
528	Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castlemans Disease (MCD).. Blood, 2007, 110, 514-514.	1.4	1
529	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. Blood, 2008, 112, 2010-2010.	1.4	1
530	A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. Blood, 2012, 120, 3709-3709.	1.4	1
531	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. Blood, 2021, 138, 1326-1326.	1.4	1
532	A novel case of gamma-delta T-cell lymphoma expressing CD4, recapitulating a stage of gamma-delta T-cell development. Blood, 2022, 139, 2725-2725.	1.4	1
533	Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression. Blood, 2022, 140, 793-793.	1.4	1
534	CSF1R/CD115 is a Helpful Marker for the Distinction of Florid Dermatopathic Lymphadenopathy From Langerhans Cell Neoplasms. American Journal of Surgical Pathology, 2023, 47, 844-846.	3.9	1
535	An AID to follicular lymphoma transformation. Blood, 2023, 142, 500-502.	1.4	1
536	B- and T-/NK-Cell Lymphomas in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms and Comparison with the WHO Fifth Edition. Hemato, 2024, 5, 157-170.	0.6	1
537	Primary Large B-cell Lymphomas of Immune-Privileged Sites. Blood, 0, , .	1.4	1
538	Rapid,de novodevelopment of isolated intracranial rosai-dorfman disease: A case report. British Journal of Neurosurgery, 2015, 29, 82-84.	0.9	0
539	Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics. , 0, , 1015-1035.		0
540	The Landscape of Cutaneous Lymphomas in 2016, An Introduction. Seminars in Diagnostic Pathology, 2017, 34, 1-2.	2.2	0

#	ARTICLE	IF	CITATIONS
541	Constipated plasma cells in extranodal marginal zone lymphoma of the lung. <i>Blood</i> , 2019, 134, 2226-2226.	1.4	0
542	Classification of the Peripheral Tâ€cell Lymphomas. , 2021, , 69-89.		0
543	Mutational Status of Chronic Lymphocytic Leukemia (CLL) Determines Clonal Evolution in Classical Hodgkinâ€™s Lymphoma Variant of Richterâ€™s Transformation.. <i>Blood</i> , 2005, 106, 2107-2107.	1.4	0
544	IL-4 Expression and Constitutive Activation of Erk Signaling In Vivo in Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 687-687.	1.4	0
545	Lymphomas including Hodgkin lymphoma. , 2008, , 1151-1165.		0
546	Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 747-747.	1.4	0
547	WHO Classification of Hematologic Malignancies. , 2014, , 219-225.e2.		0
548	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. <i>Blood</i> , 2014, 124, 1667-1667.	1.4	0
549	Whole Exome Sequencing Defines the Genetic Differences Between Pediatric and Adult Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3636-3636.	1.4	0
550	Title is missing!. , 2017, , .		0
551	Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. <i>Blood</i> , 2016, 128, 4145-4145.	1.4	0
552	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. <i>Blood</i> , 2016, 128, 4095-4095.	1.4	0
553	Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. <i>Blood</i> , 2019, 134, 4080-4080.	1.4	0
554	Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1486-1486.	1.4	0
555	Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
556	Avidinâ€™Biotin Labeling of Cellular Antigens in Cryostat-Sectioned Tissue. , 0, , 195-204.		0
557	Dural Marginal Zone Lymphoma With Extensive Crystal Storing Histiocytosis: Spotting the Zebra Among the Horses. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 658-661.	1.8	0
558	An Isolated Mesenteric Presentation of a Nodal Peripheral T Cell Lymphoma with T Follicular Helper Cell Phenotype. <i>Hematology Reports</i> , 2022, 14, 335-341.	0.9	0

#	ARTICLE	IF	CITATIONS
559	â€ˆA novel approach for characterisation of <sc>KSHV</sc>â€ˆassociated multicentric Castleman disease from effusionsâ€ˆ™: R<sc>esponse</sc>. British Journal of Haematology, 2023, 201, 360-363.	2.7	0
560	Follicular lymphoma involving the synovium inâ€ˆrheumatoid arthritis. Blood, 2023, 142, 611-611.	1.4	0
561	Evolution of Lymphoma Diagnosis in the Era of Personalized Medicine. American Journal of Pathology, 2023, 193, 1880-1886.	4.1	0
562	Peripheral Tâ€ˆcell lymphomas expressing <sc>CD30</sc> and <sc>CD15</sc> expand the spectrum of anaplastic large cell lymphoma, <sc>ALK</sc>â€ˆnegative. British Journal of Haematology, 2024, 204, 1862-1871.	2.7	0
563	Histopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma. , 2024, 4, 61-69.		0
564	Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces. Blood, 2024, 143, 2337-2337.	1.4	0
565	Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. Blood Cancer Journal, 2024, 14, .	6.3	0
566	Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms. Blood Advances, 0, , .	5.4	0